Nuformix has proposed an all-share acquisition of UK pharmaceutical developer Biovara, bringing together two respiratory drug programmes targeting lung fibrosis and lung cancer-related cough.
The proposed transaction is structured as a merger of equals and would create a larger respiratory-focused drug development business with two complementary assets, Nuformix’s NXP002 and Biovara’s LipAprep.
The proposed merger would bring together two programmes using established pharmaceutical compounds in new formulations, with the aim of improving their potential for treating respiratory conditions.
Nuformix’s NXP002 is an inhaled formulation of tranilast being developed for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis and other fibrotic interstitial lung diseases. The programme has received Orphan Drug Designation from both the US Food and Drug Administration and the European Medicines Agency.
The treatment is designed to deliver tranilast directly to the lungs, potentially achieving relevant local concentrations while limiting exposure elsewhere in the body. Preclinical studies have reported anti-fibrotic and anti-inflammatory activity in human IPF lung tissue, alongside evidence of activity in fibrosis-related pathways.
Biovara’s LipAprep is a proprietary lipid-based formulation of aprepitant, an established medicine used to prevent chemotherapy-related nausea and vomiting. It is being developed to treat persistent cough associated with lung cancer, where treatment options remain limited.
Aprepitant has previously been assessed in clinical studies for lung cancer-related cough. One controlled study reported a mean reduction of 30.3% in 24-hour cough frequency compared with placebo. LipAprep is intended to address limitations of the existing formulation and support more predictable drug exposure for longer-term treatment.
LipAprep has completed a single-ascending-dose Phase 1 study, including evaluation at doses of up to 750mg. Biovara is preparing for further clinical development, including multiple-dose assessment and a Phase 2 proof-of-concept study. Its formulation has patent protection extending to at least 2045.
The companies believe the combination could provide a broader development pipeline and opportunities to work with pharmaceutical companies interested in respiratory treatments. Nuformix’s existing discussions with potential licensing and development partners for NXP002 are continuing and are not expected to be delayed by the proposed transaction.
Under the heads of terms, Nuformix would acquire the entire issued and to be issued share capital of Biovara in exchange for new Nuformix shares. The transaction is envisaged as a merger of equals, although the combined group’s valuation and final terms have yet to be agreed.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.










































